SEARCH:   Advanced

Blood, 16 July 2009, Vol. 114, No. 3, pp. 702-708. Prepublished online as a Blood First Edition Paper on May 21, 2009; DOI 10.1182/blood-2009-03-208983. This Article Full Text Full Text (PDF) Supplemental Tables All Versions of this Article: blood-2009-03-208983v1 114/3/702    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Google Scholar Articles by Vigorito, A. C. Articles by Flowers, M. E. D. PubMed PubMed Citation Articles by Vigorito, A. C. Articles by Flowers, M. E. D. Related Collections Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD Afonso C. Vigorito1, Paulo V. Campregher2, Barry E. Storer2,3, Paul A. Carpenter2,4, Carina K. Moravec2, Hans-Peter Kiem2,5, Matthew L. Fero2,5, Edus H. Warren2,5, Stephanie J. Lee2,5, Frederick R. Appelbaum2,5, Paul J. Martin2,5, and Mary E. D. Flowers2,5 1 Bone Marrow Transplant Program at the State University of Campinas, Sao Paulo, Brazil; 2 Division of Clinical Research, Fred Hutchinson Cancer Research Center, and Departments of 3 Biostatistics, 4 Pediatrics, and 5 Medicine, University of Washington School of Medicine, Seattle Historically, graft-versus-host disease (GVHD) beyond 100 days after hematopoietic cell transplantation (HCT) was called chronic GVHD, even if the clinical manifestations were indistinguishable from acute GVHD. In 2005, the National Institutes of Health (NIH) sponsored a consensus conference that proposed new criteria for diagnosis and classification of chronic GVHD for clinical trials. According to the consensus criteria, clinical manifestations rather than time after transplantation should be used in clinical trials to distinguish chronic GVHD from late acute GVHD, which includes persistent, recurrent, or late-onset acute GVHD. We evaluated major outcomes according to the presence or absence of NIH criteria for chronic GVHD in a retrospective study of 740 patients diagnosed with historically defined chronic GVHD after allogeneic HCT between 1994 and 2000. The presence or absence of NIH criteria for chronic GVHD showed no statistically significant association with survival, risks of nonrelapse mortality or recurrent malignancy, or duration of systemic treatment. Antecedent late acute GVHD was associated with an increased risk of nonrelapse mortality and prolonged treatment among patients with NIH chronic GVHD. Our results support the consensus recommendation that, with appropriate stratification, clinical trials can include patients with late acute GVHD as well as those with NIH chronic GVHD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020